Shanghai Shen Lian Biomedical Past Earnings Performance
Past criteria checks 0/6
Shanghai Shen Lian Biomedical's earnings have been declining at an average annual rate of -25.6%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 4% per year. Shanghai Shen Lian Biomedical's return on equity is 0.7%, and it has net margins of 4.4%.
Key information
-25.6%
Earnings growth rate
-26.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -4.0% |
| Return on equity | 0.7% |
| Net Margin | 4.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Shanghai Shen Lian Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 308 | 13 | 149 | 48 |
| 31 Dec 23 | 301 | 32 | 138 | 45 |
| 30 Sep 23 | 281 | 26 | 131 | 43 |
| 30 Jun 23 | 313 | 48 | 135 | 42 |
| 31 Mar 23 | 321 | 53 | 135 | 43 |
| 31 Dec 22 | 329 | 61 | 137 | 39 |
| 30 Sep 22 | 373 | 91 | 135 | 43 |
| 30 Jun 22 | 344 | 89 | 120 | 36 |
| 31 Mar 22 | 365 | 106 | 123 | 35 |
| 31 Dec 21 | 358 | 110 | 123 | 35 |
| 30 Sep 21 | 308 | 84 | 130 | 28 |
| 30 Jun 21 | 336 | 113 | 133 | 32 |
| 31 Mar 21 | 322 | 111 | 131 | 30 |
| 31 Dec 20 | 338 | 130 | 123 | 32 |
| 30 Sep 20 | 330 | 138 | 113 | 30 |
| 30 Jun 20 | 278 | 100 | 108 | 29 |
| 31 Mar 20 | 257 | 90 | 100 | 28 |
| 31 Dec 19 | 254 | 78 | 106 | 27 |
| 31 Dec 18 | 275 | 88 | 105 | 21 |
| 31 Dec 17 | 302 | 99 | 117 | 17 |
| 30 Jun 17 | 283 | 89 | 129 | 0 |
| 31 Mar 17 | 276 | 81 | 125 | 0 |
| 31 Dec 16 | 268 | 73 | 104 | 17 |
| 31 Dec 15 | 241 | 76 | 103 | 0 |
| 31 Dec 14 | 204 | 61 | 93 | 0 |
| 31 Dec 13 | 193 | 42 | 104 | 0 |
Quality Earnings: 688098 has a large one-off gain of CN¥3.4M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 688098's current net profit margins (4.4%) are lower than last year (16.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688098's earnings have declined by 25.6% per year over the past 5 years.
Accelerating Growth: 688098's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688098 had negative earnings growth (-74.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Return on Equity
High ROE: 688098's Return on Equity (0.7%) is considered low.